A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice

Med (New York, N.y.) Pub Date : 2020-10-27 DOI:10.1101/2020.10.27.357426

Alyssa Silva-Cayetano, W. Foster, S. Innocentin, Sandra Belij-Rammerstorfer, Alexandra J. Spencer, O. Burton, Sigrid Fra-Bido, Jia Le Lee, N. Thakur, Carina Conceicao, D. Wright, J. Barrett, Nicola Evans-Bailey, Carly Noble, D. Bailey, A. Liston, S. Gilbert, T. Lambe, M. Linterman

{"title":"A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice","authors":"Alyssa Silva-Cayetano, W. Foster, S. Innocentin, Sandra Belij-Rammerstorfer, Alexandra J. Spencer, O. Burton, Sigrid Fra-Bido, Jia Le Lee, N. Thakur, Carina Conceicao, D. Wright, J. Barrett, Nicola Evans-Bailey, Carly Noble, D. Bailey, A. Liston, S. Gilbert, T. Lambe, M. Linterman","doi":"10.1101/2020.10.27.357426","DOIUrl":null,"url":null,"abstract":"The spread of SARS-CoV-2 has caused a global pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by infection, and may enable the relaxation of social distancing measures. Age is one of the most significant risk factors for poor health outcomes after SARS-CoV-2 infection, therefore it is desirable that any new vaccine candidates should elicit a robust immune response in older adults. Here, we test the immunogenicity of the adenoviral vectored vaccine ChAdOx1 nCoV-19 (AZD-1222) in aged mice. We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice. Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.","PeriodicalId":272244,"journal":{"name":"Med (New York, N.y.)","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"64","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med (New York, N.y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2020.10.27.357426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 64

Abstract

The spread of SARS-CoV-2 has caused a global pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by infection, and may enable the relaxation of social distancing measures. Age is one of the most significant risk factors for poor health outcomes after SARS-CoV-2 infection, therefore it is desirable that any new vaccine candidates should elicit a robust immune response in older adults. Here, we test the immunogenicity of the adenoviral vectored vaccine ChAdOx1 nCoV-19 (AZD-1222) in aged mice. We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice. Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.

查看原文本刊更多论文

增强剂增强了COVID-19候选疫苗ChAdOx1 nCoV-19在老年小鼠中的免疫原性

SARS-CoV-2的传播引发了一场全球大流行，几乎影响了人类生活的方方面面。开发有效的COVID-19疫苗可以限制感染引起的发病率和死亡率，并有可能放松社交距离措施。年龄是导致SARS-CoV-2感染后健康状况不佳的最重要危险因素之一，因此，希望任何新的候选疫苗都能在老年人中引起强有力的免疫反应。在此，我们测试了腺病毒载体疫苗ChAdOx1 nCoV-19 (AZD-1222)在老年小鼠中的免疫原性。我们发现，单剂量这种疫苗在老年小鼠中诱导细胞和体液免疫，但其程度低于年轻成年小鼠。此外，我们报告说，第二次剂量可以增强老年小鼠对该疫苗的免疫反应，这表明初始增强策略可能是增强老年人免疫原性的合理方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med (New York, N.y.)

自引率

0.00%

发文量